Terray Therapeutics has successfully raised $120 million in a Series B funding round to advance its AI-powered small-molecule drug development. The funding round was led by Bedford Ridge Capital and Nvidia's NVentures. CEO Jacob Berlin stated that the company aims to get its lead drug candidate into the clinic by 2026, leveraging its proprietary hardware in microarray chips to fuel its AI ambitions. Meanwhile, Seaport Therapeutics, a PureTech-founded entity, has closed a $225 million oversubscribed Series B financing round. This brings the total raised by Seaport to $325 million since its launch in April 2024. The funds will support the development of novel neuropsychiatric medicines, marking a significant milestone in the company's journey to embrace the 'golden age of neuroscience.' Seaport Therapeutics is listed under the ticker $PRTC.